BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 30665034)

  • 21. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
    Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
    Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
    Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
    [No Abstract]   [Full Text] [Related]  

  • 27. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.
    Akhtar MJ; Siddiqui AA; Khan AA; Ali Z; Dewangan RP; Pasha S; Yar MS
    Eur J Med Chem; 2017 Jan; 126():853-869. PubMed ID: 27987485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and in vitro antitumor evaluation of new thieno[2,3-d]pyrimidine derivatives as EGFR and DHFR inhibitors.
    Fouad MM; Ghabbour HA; Shehata IA; El-Ashmawy MB
    Bioorg Chem; 2024 Jul; 148():107401. PubMed ID: 38749115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.
    El-Mawgoud HKA; Fouda AM; El-Nassag MAA; Elhenawy AA; Alshahrani MY; El-Agrody AM
    Chem Biol Interact; 2022 Mar; 355():109838. PubMed ID: 35123995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of apoptosis, cytotoxicity and radiosensitization by novel 3,4-dihydroquinazolinone derivatives.
    Soliman AM; Khalil A; Ramadan E; Ghorab MM
    Bioorg Med Chem Lett; 2021 Oct; 49():128308. PubMed ID: 34363937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
    El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
    Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
    Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
    Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF
    El-Damasy AK; Haque MM; Park JW; Shin SC; Lee JS; EunKyeong Kim E; Keum G
    Eur J Med Chem; 2020 Dec; 208():112756. PubMed ID: 32942186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
    Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
    Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.